Publications by authors named "Peter Greasley"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

3,122

Total Likes

360

Extended Reach

301,694

Social Features

72
A
A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment.
Macarena Paz Quintana-Hayashi, Kathleen Connolly, Peter Greasley, Melanie Chan, Masood Sadaat

Am J Cardiol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD.
Mark André de la Rambelje, Adriaan A Voors, Peter J Greasley, Mario Berger, Hiddo J L Heerspink

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis.
Rhoda E Kuc, Anna L Paterson, Thomas L Williams, William T H Gelson, Peter J Greasley

Front Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein profiles and associated biological pathways among different etiologies of chronic kidney disease: new insights from DAPA-CKD.
Mark André de la Rambelje, Iris E Beldhuis, Hiddo J L Heerspink, Peter J Greasley, Rasmus Agren

Nephrol Dial Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-up.
Vancheswaran Gopalakrishnan, Chanchal Kumar, Ida Robertsen, Christopher Morehouse, Ben Sparklin, Peter J Greasley

Mucosal Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
Victor Wasehuus, J David Smeijer, Phil Ambery, Peter J Greasley, Emma Wijkmark

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Jelle M Beernink, Niels Jongs, Charlotte M Mosterd, Rosalie A Scholtes, Alyssa Caldwell-McGee, Peter J Greasley

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney transcriptomics signature of prospective rapid diabetic kidney disease progression.
Dianne Acoba, Anna Levin, Anna Witasp, Kerstin Ebefors, Johan Mölne, Peter J Greasley

BMC Nephrol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.
Laura H Mariani, Howard Trachtman, Aliza Thompson, Barbara S Gillespie, Michelle Denburg, Peter J Greasley

Am J Kidney Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial.
Hongtao Yu, Peter J Greasley, Hiddo J Lambers Heerspink, Philip Ambery, Christine Ahlstrom

Br J Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of endothelin-1 and effect selective ET antagonism on ET activation: a mathematical modeling analysis.
K Melissa Hallow, Peter J Greasley, Hiddo J L Heerspink, Hongtao Yu

Front Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, José Luis Górriz, Maria José Soler, Peter J Greasley

J Am Soc Nephrol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled Trial.
Cecilia Karlsson, Line Kristin Johnson, Peter J Greasley, Kjetil Retterstøl, Jonatan Hedberg

JAMA Surg· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Phil Ambery, Peter J Greasley

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue.
Thomas L Williams, Rhoda E Kuc, Anna L Paterson, George R Abraham, Anna L Pullinger, Peter J Greasley

Biosci Rep· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni

Clin Sci (Lond)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis.
Hongtao Yu, Peter Greasley, Hiddo Lambers-Heerspink, David W Boulton, Bengt Hamrén

Front Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Hiddo J L Heerspink, Peter J Greasley, Christine Ahlström, Magnus Althage, Jamie P Dwyer

Nephrol Dial Transplant· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
Subodh Verma, Sunder Mudaliar, Peter J Greasley

Adv Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Hiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, Min Lin, Emma Wijkmark, Peter J Greasley

Lancet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Akihiko Koshino, Brendon L Neuen, Niels Jongs, Carol Pollock, Peter J Greasley

Cardiovasc Diabetol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study.
Nerissa Hoi Ching Lee, Steven J Kiddle, Shardul Chandankhede, Shubh Agrawal, Daniel M Bean, Peter J Greasley

BMJ Open Gastroenterol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and future strategies for targeting the endothelin pathway in cardiovascular disease.
George R Abraham, Thomas L Williams, Janet J Maguire, Peter J Greasley, Philip Ambery

Nat Cardiovasc Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOL1 promotes endothelial cell activation beyond the glomerulus.
Miguel Carracedo, Elke Ericson, Rasmus Ågren, Anna Forslöw, Katja Madeyski-Bengtson, Peter J Greasley

iScience· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis